In AML, BET inhibitors are thought to act largely by inhibiting the expression of c-Myc and, consequently, block the self-renewal and survival of leukemia cells (Delmore et al., 2011; Grayson et al., 2014; Mertz et al., 2011; Zuber et al., 2011b). This evidence concerns the gene MYC and acute myeloid leukemia.